Among candidate biomarkers for human BC considerable attention has been focused recently on the combination of the Urokinase-dependent plasminogen activator system (uPA), Plasinogen activator inhibitor (PAI) and the Thomsen-Friedenreich antigen (TF). The gene discussed is PLAU; the disease is breast cancer.